Salvage radiation in men after prostate-specific antigen failure and the risk of death

Cancer. 2011 Sep 1;117(17):3925-32. doi: 10.1002/cncr.25993. Epub 2011 Mar 22.

Abstract

Background: A survival benefit has been observed with salvage radiation therapy (RT) for prostate-specific antigen (PSA) failure after radical prostatectomy (RP) in men with rapid rises in PSA doubling time (DT, < 6 months). Whether such a benefit exits in men with a protracted PSA rise in DT (≥ 6 months) is unclear and was examined in the current study.

Methods: Of 4036 men who underwent RP at Duke University between 1988 and 2008, 519 experienced a PSA failure, had complete data, and were the subjects of this study. Univariate and multivariate Cox regression analyses were performed to evaluate whether salvage RT in men with either a rapid (< 6 months) or a protracted (≥ 6 months) PSA DT was associated with the risk of all-cause mortality adjusting for age at the time of PSA failure, known prostate cancer prognostic factors, and cardiac comorbidity.

Results: After a median follow-up of 11.3 years after PSA failure, 195 men died. Salvage RT was associated with a significant reduction in all-cause mortality for men with either a PSA DT of < 6 months (adjusted hazard ratio [AHR], 0.53; P = .02) or a PSA DT of ≥ 6 months (AHR, 0.52; P = .003). In a subset of patients with comorbidity data at the time of PSA failure, salvage RT remained associated with a significant reduction in all-cause mortality for both men with a PSA DT of < 6 months (AHR, 0.35; P = .042) or a PSA DT of ≥ 6 months (AHR, 0.60; P = .04).

Conclusions: Salvage RT for PSA DTs less than or in excess of 6 months is associated with a decreased risk in all-cause mortality.

MeSH terms

  • Aged
  • Androgen Antagonists / therapeutic use
  • Cause of Death
  • Follow-Up Studies
  • Heart Diseases / complications
  • Humans
  • Male
  • Middle Aged
  • Prostate-Specific Antigen / metabolism*
  • Prostatectomy
  • Prostatic Neoplasms / complications
  • Prostatic Neoplasms / metabolism
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / radiotherapy*
  • Recurrence
  • Retrospective Studies
  • Risk Assessment
  • Salvage Therapy
  • Treatment Failure

Substances

  • Androgen Antagonists
  • Prostate-Specific Antigen